Close

FibroGen IPO Info

Company Name: FibroGen
Stock Symbol: FGEN
Exchange: NASDAQ
Status: Priced
IPO Date: 11/14/2014
IPO Price: 18.00 (51.89%)
Underwriters
Goldman, Sachs & Co., Citigroup, and Leerink

Amount of Offering: N/A
Number of Shares Offered: 8.1 Mil
Shares Outstanding After Offering: N/A
Valuation: N/A
Company Description
FibroGen is a research-based biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs. We have capitalized on our extensive experience in fibrosis and hypoxia-inducible factor, or HIF, biology to generate multiple programs targeting various therapeutic areas. Our most advanced product candidate, roxadustat, or FG-4592, is an oral small molecule inhibitor of HIF prolyl hydroxylases, or HIF-PHs, in Phase 3 clinical development for the treatment of anemia in chronic kidney disease, or CKD. Our second product candidate, FG-3019, is a monoclonal antibody in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis, or IPF, pancreatic cancer and liver fibrosis. We have taken a global approach to the development and future commercialization of our product candidates, and this includes development and commercialization in the People’s Republic of China, or China.

News Headlines